...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome.
【24h】

The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome.

机译:利用克罗巴唑作为Lennox-Gastaut综合征的辅助治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

Clobazam, a 1,5-benzodiazepine, has been available in many European countries since the 1970s, both as an anxiolytic and as an antiepileptic. Recently, it has been marketed in the U.S. for the adjunctive treatment of Lennox-Gastaut syndrome, a seizure disorder accompanied by mental retardation and/or learning difficulties. The condition is usually refractory to many antiepileptic agents. The pivotal phase II and III trials of adjunctive clobazam are reviewed together with its postulated mode of action, pharmacokinetics and drug interaction profile. The data are discussed in terms of existing FDA-approved agents for Lennox-Gastaut syndrome and suggestions for further work.
机译:自20世纪70年代以来,许多欧洲国家在许多欧洲国家提供了1,5-苯并二氮杂,无论是抗焦虑还是作为抗癫痫症。 最近,它已经在美国销售了Lennox-Gastaut综合征的辅助治疗,癫痫发作症伴有精神发育迟滞和/或学习困难。 这种情况通常对许多抗癫痫药物难以忍受。 辅助克罗巴唑的枢轴期II和III试验与其假定的作用方式,药代动力学和药物相互作用谱进行审查。 这些数据是根据现有的FDA批准的代理商用于Lennox-Gastaut综合征和进一步工作的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号